Mechanisms of monoclonal antibody-drug interactions

Annual Review of Pharmacology and Toxicology

Volumn 51, Issue , 2011, Pages 359-372

  Zhou, Honghui ^a   Mascelli, Mary Ann ^a  

^a CENTOCOR INC   (United States)

Author keywords

cytokine; disease drug interaction; pharmacokinetics

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CAPROMAB PENDETIDE IN 111; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; FANOLESOMAB TC 99M; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; NOFETUMOMAB MERPENTAN TC 99M; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG; VERAPAMIL;

ACUTE GRAFT REJECTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHIMERA; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG INTOXICATION; DRUG MECHANISM; HUMAN; INFECTION; LONG TERM CARE; METABOLIC DISORDER; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

MURINAE;

EID: 79952001750     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100510     Document Type: Article

References (77)

1. Ehrlich P. 1891. Experimentelle untersuchungen über immunitat. I. Ueber ricin. Dtsch. Med. Wochenschr. 17:976-79
2. Lindenmann J. 1984. Origin of the terms "antibody" and "antigen." Scand. J. Immunol. 194:281-85
3. RajuTN. 1999. The Nobel chronicles. 1972: GeraldMEdelman(b 1929) and Rodney R Porter (1917-85). Lancet 354(9183):1040
4. Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 845:548-58
5. Lee J-I, Zhang L, Men AY, Kenna LA, Huang S-M. 2010. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 495:295-310
6. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Tessler Lindau S, et al. 2008. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. J. Am. Med. Assoc. 300(24):2867-78
7. Seitz K, Zhou H. 2007. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J. Clin. Pharmacol. 47:1104-18
8. MahmoodI, GreenMD. 2007. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J. Clin. Pharmacol. 47:1540-54 (Pubitemid 350115304)
9. Zhou H, Davis HM. 2009. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov. Today 14:891-98
10. Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, et al. 2010. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87:497-503
11. Theil FP. 2008. Current knowledge on clearance mechanisms: drug-drug interaction potential for monoclonal antibodies with other protein biotherapeutics and small molecule drugs. Presented at AAPS Natl. Biotechnol. Conf, June 22-25, Toronto
12. Brambell FWR, Hemmings WA, Morris IG. 1964. A theoretical model of y-globulin catabolism. Nature 203:1352-55
13. Brambell FW. 1966. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 2:1087-93
14. Ghetie V, Hubbard JG, Kim JK, TsenMF, Lee Y, et al. 1996. Abnormally short serum half-lives of IgG in |32-microglobulin-deficient mice. Eur. J. Immunol. 26:690-96 (Pubitemid 26091401)
15. Junghans RP. 1997. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol. Res. 16:29-57
16. Ghetie V, Ward ES. 1997. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol. Today 18:592-98 (Pubitemid 28012280)
17. Ghetie V, Ward ES. 2002. Transcytosis and catabolism of antibody. Immunol. Res. 25:97-113 (Pubitemid 34264097)
18. Morgan ET. 1997. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. 29:1129-88 (Pubitemid 28133460)
19. Prandota J. 2005. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am. J. Ther. 12:254-61 (Pubitemid 40825131)
20. Morgan ET. 2009. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. 85:434-38
21. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, et al. 2008. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos. 36:205-16 (Pubitemid 351185732)
22. LeVee LM, Lecureur V, Stieger B, Fardel O. 2009. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor- a. or interleukin-6. Drug Metab. Dispos. 37:685-93
23. AitkenAE, Richardson TA,MorganET. 2006. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46:123-49 (Pubitemid 43271186)
24. Kato R, Nakamura Y, Chiesara E. 1963. Enhanced phenobarbital induction of liver microsomal drug-metabolizing enzymes in mice infected with murine hepatitus virus. Biochem. Pharmacol. 12:365-70
25. Chang KC, Lauer BA, Bell TD, Chai H. 1978. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 311:1132-33 (Pubitemid 8356442)
26. Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE, Bierman CW. 1982. Altered theophylline clearance during an influenza B outbreak. Pediatrics 69:476-80 (Pubitemid 12135951)
27. Leeson GA, Biedenbach SA, Chan KY, Gibson JP, Wright GJ. 1976. Decrease in the activity of the drug-metabolizing enzymes of rat liver following the administration of tilorone hydrochloride. Drug Metab. Dispos. 4:232-38
28. Renton KW, Mannering GJ. 1976. Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem. Biophys. Res. Commun. 73:343-48
29. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, et al. 1993. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol. 44:707-15 (Pubitemid 23317282)
30. Cribb AE, Delaporte E, Kim SG, Novak RF, Renton KW. 1994. Regulation of cytochrome P-4501A and cytochrome P-4502E induction in the rat during the production of interferon a/|3. J. Pharmacol. Exp. Ther. 268:487-94 (Pubitemid 24039126)
31. Delaporte E, Renton KW. 1997. Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon- a/13 induction. Life Sci. 60:787-96 (Pubitemid 27087271)
32. DonatoMT, Guillen MI, Jover R, Castell JV, Gomez-LechonMJ. 1997. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-y in human hepatocytes. J. Pharmacol. Exp. Ther. 281:484-90 (Pubitemid 27203106)
33. Islam M, Frye RF, Richards TJ, Sbeitan I, Donnelly SS, et al. 2002. Differential effect of IFNa-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin. Cancer Res. 8:2480-87 (Pubitemid 34856329)
34. Williams SJ, Baird-Lambert JA, Farrell GC. 1987. Inhibition of theophylline metabolism by interferon. Lancet 330:939-41 (Pubitemid 17150287)
35. Singh G, Renton KW. 1981. Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation. Mol. Pharmacol. 20:681-84 (Pubitemid 12252294)
36. Renton KW. 1981. Depression of hepatic cytochrome P-450-dependent mixed function oxidases during infection with encephalomyocarditis virus. Biochem. Pharmacol. 30:2333-36 (Pubitemid 11048325)
37. Meredith CG, Christian CD, Johnson RF, Troxell R, Davis GL, Schenker S. 1985. Effects of influenza virus vaccine on hepatic drug metabolism. Clin. Pharmacol. Ther. 37:396-401 (Pubitemid 15238884)
38. Chow HH, Tang Y, Li P, Brookshier G, Liang B, Watson R. 1998. The effect of chronic retrovirus infection and immune dysfunction on the P-450-mediated activation of acetaminophen in mouse liver microsomes. Biopharm. Drug Dispos. 19:9-15 (Pubitemid 28064486)
39. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, et al. 2010. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur. J. Clin. Pharmacol. 66:475-85
40. Samaras SC,DietzN 1953. Physiopathology of detoxification of pentobarbital sodium. FASEBJ. 12:122-25
41. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA. 1994. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Investig. 94:2209-14
42. Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, et al. 1994. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin. Pharmacol. Ther. 55:649-60 (Pubitemid 24212266)
43. Sakamoto K, Arakawa H, Mita S, Ishiko T, Ikei S, et al. 1994. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine 6:181-86 (Pubitemid 24263857)
44. Gidal BE, Reiss WG, Liao JS, Pitterle ME. 1996. Changes in interleukin-6 concentrations following epilepsy surgery: potential influence on carbamazepine pharmacokinetics. Ann. Pharmacother. 30:545-46 (Pubitemid 26139256)
45. Aitken AE, Morgan ET. 2007. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNAlevels in human hepatocytes. Drug Metab. Dispos. 35:1687-93 (Pubitemid 47296065)
46. Ling S, Jamali F. 2005. Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug. Metab. Dispos. 33:579-86 (Pubitemid 40393202)
47. Dipasquale G, Welaj P, Rassaert CL. 1974. Prolonged pentobarbital sleeping time in adjuvant-induced polyarthritic rats. Res. Commun. Chem. Pathol. Pharmacol. 9:253-64
48. Baumgartner WA, Beck FW, Lorber A, Pearson CM, Whitehouse MW. 1974. Adjuvant disease in rats: biochemical criteria for distinguishing several phases of inflammation and arthritis. Proc. Soc. Exp. Biol. Med. 145:625-30
49. Guirguis MS, Jamali F. 2003. Disease-drug interaction: reduced response to propranolol despite increased concentration in the rat with inflammation. J. Pharm. Sci. 92:1077-84 (Pubitemid 36523454)
50. Ling S, Jamali F. 2009. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin. Pharmacol. Toxicol. 105:24-29
51. Schneider RE, Babb J, Bishop H, Mitchard M, Hoare AM. 1976. Plasma levels of propranolol in treated patients with celiac disease and patients with Crohn's disease. Br. Med. J. 2:794-95
52. Mayo PR, Skeith K, Russell AS, Jamali F. 2000. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmacol. 50:605-13 (Pubitemid 32010020)
53. Ling S, Lewanczuk RZ, Russell AS, Ihejirika B, Jamali F. 2009. Influence of controlled rheumatoid arthritis on the action and disposition of verapamil: focus on infliximab. J. Clin. Pharmacol. 49:301-11
54. Zhang X, Schmitt C, Grange S, Terao K, Miya K. 2009. Disease-drug interaction studies of tocilizumab with cytochrome p450 substrate in vitro and in vivo. Clin. Pharmacol. Ther. 85:S59 (Abstr.)
55. Khatsenko OG, Gross SS, Rifkind AB, Vane J. 1993. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc. Natl. Acad. Sci. USA 90:11147-51 (Pubitemid 23354386)
56. Balthasar JP. 2010. An academic view of therapeutic protein drug-drug interactions. Presented at AAPS Workshop Ther. Protein Drug Interact., May 15-16, San Francisco
57. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a. monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1552-63 (Pubitemid 28459913)
58. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Eng. J. Med. 348:601-8 (Pubitemid 36204954)
59. Humira [package insert]. Chicago, IL: Abbott Laboratories; 2002
60. Xu Z, Vu T, Lee H, Hu C, Ling J, et al. 2009. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-a human monoclonal antibody, in patients with psoriatic arthritis. J. Clin. Pharmacol. 49:1056-70
61. Aikawa NE, Freire de Carvalho FJ, Silva CAA, Bonfa E. 2010. Immunogenicity of anti-TNF-a agents in autoimmune diseases. Clin. Rev. Allergy Immunol. 38:82-89
62. M p2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J. Rheumatol. 31:2347-55 (Pubitemid 39603080)
63. Zhou H, Mayer PR, Wajdula J, Fatenejad S. 2004. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J. Clin. Pharmacol. 44:1235-43 (Pubitemid 39391482)
64. De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, et al. 2009. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68:531-35
65. Kovarik JM, Pescovitz MD, Sollinger HW, Kaplan B, Legendre C, et al. 2001. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin. Transplant. 15:123-30 (Pubitemid 32229801)
66. Kimball JA, Pescovitz MD, Book BK, Norman DJ. 1995. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 60:1379-83 (Pubitemid 26018420)
67. Smith KGC, Isbel NM, Catton MG, Leydon JA, Becker GJ, et al. 1998. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol. Dial. Transplant. 13:160-164 (Pubitemid 28033597)
68. Levy J, Barnett EV, MacDonald NS, Klinenberg JR, Pearson CM. 1972. The effect of azathioprine on gammaglobulin synthesis in man.J. Clin. Investig. 51:2233-38
69. Herceptin® [package insert]. San Francisco: Genentech Inc.; 2003
70. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, et al. 2005. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother. Pharmacol. 56:361-69 (Pubitemid 41095399)
71. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S. 2003. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. 21:3965-71 (Pubitemid 46606210)
72. Tange S, Scherer MN, Graeb C, Weiss T, Justl M, et al. 2002. The antineoplastic drug paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 73:216-23 (Pubitemid 34112843)
73. Oude Munnink TH, Dijkers EC, Netters SJ, Lub-de Hooge MN, Brouwers AH, et al. 2010. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J. Clin. Oncol. 28:e355-56
74. Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93:5512-16
75. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, et al. 2006. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leukemia Lymphoma 47:998-1005
76. Barni S, Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M. 2007. From the trastuzumab era to new target therapies: beyond revolution. Ann. Oncol. 18(Suppl. 6):vi1-4
77. Hansen RJ, Balthasar JP. 2002. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100:2087-93 (Pubitemid 35001242)